共 147 条
[1]
DiMasi JA(2016)Innovation in the pharmaceutical industry: new estimates of R&D costs J Health Econ. 47 20-33
[2]
Grabowski HG(2019)Conducting clinical trials—costs, impacts, and the value of clinical trials networks: a scoping review Clin Trials. 16 183-193
[3]
Hansen RW(2018)Adaptive designs in clinical trials: why use them, and how to run and report them BMC Med. 16 1-15
[4]
Bentley C(2020)The Adaptive designs CONSORT Extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design BMJ. 369 m115-180
[5]
Cressman S(2020)Adding flexibility to clinical trial designs: an example-based guide to the practical use of adaptive designs BMC Med. 18 352-346
[6]
van der Hoek K(2018)Practical characteristics of adaptive design in phase 2 and 3 clinical trials J Clin Pharm Ther. 43 170-16
[7]
Arts K(2018)Adaptive design clinical trials: a review of the literature and ClinicalTrials.gov BMJ Open 8 e018320-10
[8]
Dancey J(2013)Uptake of novel statistical methods for early-phase clinical studies in the UK public sector Clin Trials. 10 344-497
[9]
Peacock S(2015)Missing steps in a staircase: a qualitative study of the perspectives of key stakeholders on the use of adaptive designs in confirmatory trials Trials. 16 1-11
[10]
Pallmann P(2020)Stakeholder perspectives on adaptive clinical trials: A scoping review Trials. 21 1-100

